论文信息 - Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment.

Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment.

The chimeric monoclonal anti-CD20 antibody has been widely used for the treatment of relapsed or refractory low-grade B-cell non-Hodgkin lymphoma (NHL). However, in patients with a high number of tumor cells in blood, severe infusion-related toxicities have been reported.[1][1] On the basis of

[1] V. Diehl,et al. CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8) , 2016 .

[2] J. Byrd,et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3] R. Mertelsmann,et al. Leukostasis followed by hemorrhage complicating the initiation of chemotherapy in patients with acute myeloid leukemia and hyperleukocytosis , 1999, Cancer.

[4] J. Schuur,et al. Acute cardiorespiratory failure as presenting symptom of chronic lymphocytic leukemia. , 1996, The Netherlands journal of medicine.

[5] M. van Buchem,et al. Involvement of the complement system in the pathogenesis of pulmonary leukostasis in experimental myelocytic leukemia. , 1993, Leukemia.